Viral hemorrhagic fevers (VHFs) refer to a group of illnesses that are caused by several distinct families of viruses. In general, the term "viral hemorrhagic fever" is used to describe a severe multisystem syndrome (multisystem in that multiple organ systems in the body are affected). Characteristically, the overall vascular system is damaged, and the body's ability to regulate itself is impaired. These symptoms are often accompanied by hemorrhage (bleeding); however, the bleeding is itself rarely life-threatening. While some types of hemorrhagic fever viruses can cause relatively mild illnesses, many of these viruses cause severe, life-threatening disease.
For most people who contract it, dengue fever is a relatively mild-mannered disease--at least the first time around. For some, however, a subsequent infection by the virus unleashes a vicious and potentially deadly illness.
The Georgia State University Research Foundation has entered into a research collaboration agreement with GeoVax Labs, Inc., a Georgia-based biotechnology company developing human vaccines, to advance development of a therapeutic vaccine for treatment of chronic Hepatitis B infections.
The only approved vaccine for dengue may actually increase the incidence of dengue infections requiring hospitalization rather than preventing the disease if health officials aren't careful about where they vaccinate, new public health research published Sept. 2 in Science suggests.
Scientists at The Scripps Research Institute now have a high-resolution view of exactly how the experimental therapy ZMapp targets Ebola virus.
A newly identified requirement of a modified human protein in ebolavirus (EBOV) replication, may unlock the door for new approaches to treating Ebola.
A biopharmaceutical company collaborating with Hawai'i scientists on an Ebola vaccine announced encouraging news about its vaccine today.
Viruses can't live without us -- literally. As obligate parasites, viruses need a host cell to survive and grow. Scientists are exploiting this characteristic by developing therapeutics that close off pathways necessary for viral infection, essentially stopping pathogens in their tracks.
Ebola virus samples taken from patients in Liberia in June 2015 are strikingly similar in their genetic makeup to other Ebola virus sequences from Western Africa, according to research published online today in the journal Science Advances. The study sheds light on several aspects of the "flare-ups" that have occurred in Liberia since the country was initially declared free of Ebola virus disease.
As of January 31, 2016, a total of 28,639 cases and 11,316 deaths have been attributed to Ebola, figures that are assumed to significantly underestimate the actual scope of the 2014 Ebola Hemorrhagic Fever outbreak in West Africa. In the United States, there were also two imported cases and two locally acquired cases reported in September/October 2014.
In a small clinical trial led by the Johns Hopkins Bloomberg School of Public Health, researchers say that a promising single-dose dengue vaccine, developed by scientists at the National Institutes of Health, was 100 percent effective in preventing human volunteers from contracting the virus, the most prevalent mosquito-borne virus in the world.
A single monoclonal antibody isolated from a human survivor of Ebola virus disease (EVD) completely protected monkeys from lethal infection with the virus, according to research published in today's online edition of the journal Science.
The Institute for Research in Biomedicine, affiliated to the Università della Svizzera italiana, and Humabs BioMed SA, a Swiss antibody therapeutics company, have identified, isolated and characterized two Ebola virus neutralizing monoclonal antibodies from the blood of a survivor of an Ebola infection.
Profectus BioSciences, Inc., a clinical-stage vaccine company developing novel vaccines for the prevention and treatment of infectious diseases and the treatment of cancer, announced today the initiation of a Phase 1 clinical study of Profectus' VesiculoVax-vectored Ebola virus vaccine.
Researchers at Albert Einstein College of Medicine and the U.S. Army Medical Research Institute of Infectious Diseases have engineered the first antibodies that can potently neutralize the two deadliest strains of the virus that causes Ebola hemorrhagic fever.
When the Ebola virus outbreak erupted in West Africa in 2014, children infected with the virus -- particularly those under age 5 -- faced overwhelming challenges. Not only was there a high death rate among young children infected with the disease, they often were isolated from their families, leaving them feeling distressed and without the intensive care they needed.
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a study in The Journal of Infectious Diseases.
An international team of researchers, including Ahmed Abd El Wahed, scientist at the University of Göttingen and the German Primate Center, has tested a new method for rapid diagnosis of Ebola in a field trial in Guinea. The test procedure was carried out using a portable suitcase laboratory. The mobile suitcase lab is operated with solar power and enables simple on-site diagnostics in remote areas without the need of an equipped laboratory.
The Ebola virus acts fast. The course of infection, from exposure to recovery, or death, can take as little as two weeks. That may not leave enough time for the immune system to mount an effective response.
A suspected case of sexual transmission of Ebola virus disease (EVD) in Liberia was confirmed using genomic analysis, thanks to in-country laboratory capabilities established by U.S. Army scientists in collaboration with the Liberian Institute for Biomedical Research (LIBR).
The first-ever comprehensive genomic analysis of the virus that causes dengue fever suggests that it may survive year-round in southern China.